Ionis Pharmaceuticals Inc (IONS) Director Joseph Klein III Sells 3,000 Shares

Ionis Pharmaceuticals Inc (NASDAQ:IONS) Director Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock in a transaction on Friday, December 29th. The shares were sold at an average price of $50.56, for a total value of $151,680.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Joseph Klein III also recently made the following trade(s):

  • On Saturday, December 29th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $50.56, for a total value of $151,680.00.
  • On Friday, December 15th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $51.69, for a total value of $155,070.00.
  • On Thursday, November 30th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $53.55, for a total value of $160,650.00.
  • On Wednesday, November 15th, Joseph Klein III sold 2,250 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $53.56, for a total value of $120,510.00.
  • On Monday, November 13th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $55.39, for a total value of $166,170.00.

Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) opened at $49.25 on Wednesday. The firm has a market capitalization of $6,277.21, a price-to-earnings ratio of 328.36 and a beta of 2.86. Ionis Pharmaceuticals Inc has a 52-week low of $37.26 and a 52-week high of $65.51. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25.

Several equities analysts have issued reports on IONS shares. Stifel Nicolaus reiterated a “hold” rating and issued a $50.00 price objective on shares of Ionis Pharmaceuticals in a research report on Friday, October 13th. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $62.00 price objective for the company in a research report on Friday, October 27th. BidaskClub upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, December 7th. Morgan Stanley lifted their price objective on Ionis Pharmaceuticals from $45.00 to $49.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 8th. Finally, BMO Capital Markets lifted their price objective on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, November 8th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $50.31.

Several hedge funds have recently added to or reduced their stakes in IONS. Russell Investments Group Ltd. raised its position in shares of Ionis Pharmaceuticals by 21.4% during the second quarter. Russell Investments Group Ltd. now owns 20,077 shares of the company’s stock worth $1,021,000 after acquiring an additional 3,538 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Ionis Pharmaceuticals by 17.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 367,550 shares of the company’s stock worth $18,698,000 after acquiring an additional 54,587 shares during the last quarter. Advisors Asset Management Inc. raised its position in shares of Ionis Pharmaceuticals by 30.8% during the second quarter. Advisors Asset Management Inc. now owns 8,558 shares of the company’s stock worth $435,000 after acquiring an additional 2,016 shares during the last quarter. State of Wisconsin Investment Board raised its position in shares of Ionis Pharmaceuticals by 2.3% during the second quarter. State of Wisconsin Investment Board now owns 24,616 shares of the company’s stock worth $1,252,000 after acquiring an additional 550 shares during the last quarter. Finally, SG Americas Securities LLC increased its holdings in Ionis Pharmaceuticals by 30.9% in the second quarter. SG Americas Securities LLC now owns 6,315 shares of the company’s stock valued at $321,000 after purchasing an additional 1,489 shares during the last quarter. Institutional investors own 91.40% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Ionis Pharmaceuticals Inc (IONS) Director Joseph Klein III Sells 3,000 Shares” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.chaffeybreeze.com/2018/01/03/ionis-pharmaceuticals-inc-ions-director-joseph-klein-iii-sells-3000-shares-2.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply